<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00266565</url>
  </required_header>
  <id_info>
    <org_study_id>01-9-18</org_study_id>
    <secondary_id>FD-R-002396</secondary_id>
    <nct_id>NCT00266565</nct_id>
  </id_info>
  <brief_title>Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome</brief_title>
  <official_title>A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Toxicity of anti-IL-5&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to assess the toxicity of anti-IL-5, and to see whether it lowers&#xD;
      peripheral blood eosinophils and/or tissue and whether it has a steroid and/or interferon&#xD;
      sparing effect.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2001</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the toxicity of anti-IL-5 in patients with hypereosinophilia</measure>
    <time_frame>28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess whether anti-IL-5 lowers peripheral blood eosinophils and/or tissue in patients with hypereosinophilia</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess whether anti-IL-5 has a steroid and/or interferon sparing effect</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hypereosinophilic Syndromes</condition>
  <condition>Eosinophilic Gastroenteritis</condition>
  <condition>Churg-Strauss Syndrome</condition>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Anti-IL5 (Mepolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mepolizumab</intervention_name>
    <description>10mg/kg (max 750 ml) once a month for 3 months</description>
    <arm_group_label>Anti-IL5 (Mepolizumab)</arm_group_label>
    <other_name>Anti-IL5</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adequate renal, cardiac, and hepatic function&#xD;
&#xD;
          -  Not pregnant or breastfeeding&#xD;
&#xD;
          -  A diagnosis of hypereosinophilic syndrome such as:&#xD;
&#xD;
               -  Idiopathic hypereosinophilic syndrome;&#xD;
&#xD;
               -  Eosinophilia myalgia syndrome;&#xD;
&#xD;
               -  Eosinophilic gastroenteritis;&#xD;
&#xD;
               -  Churg-Strauss syndrome;&#xD;
&#xD;
               -  Eosinophilic cellulitis;&#xD;
&#xD;
               -  Benign hypereosinophilia; or&#xD;
&#xD;
               -  Eosinophilic esophagitis.&#xD;
&#xD;
          -  Maintained on, or in need of, the following: glucocorticoids, interferon,&#xD;
             methotrexate, hydroxyurea, cytoxan, 6-mercaptopurine, or vincristine&#xD;
&#xD;
          -  Blood eosinophil counts greater than 750 cells/mcl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine &gt; 3 X upper limit for age&#xD;
&#xD;
          -  AST &gt; 5 X upper limit for age&#xD;
&#xD;
          -  Platelet count &lt; 50,000/mm3&#xD;
&#xD;
          -  Cardiac function:&#xD;
&#xD;
               1. NYHA class IIIb or IV (patients with shortness of breath or fatigue with mild&#xD;
                  exertion or at rest);&#xD;
&#xD;
               2. Patients with symptomatic supraventricular or ventricular arrythmias requiring&#xD;
                  treatment;&#xD;
&#xD;
               3. Patients requiring IV heart failure medications;&#xD;
&#xD;
               4. Angina or acute myocardial infarction&#xD;
&#xD;
          -  History of renal, hepatic, endocrine, oncologic, cardiovascular disease, or any other&#xD;
             condition which, in the opinion of the Investigator, would jeopardize the safety of&#xD;
             the patient or impact on the validity of the study results&#xD;
&#xD;
          -  History of allergic or adverse response to previous antibody type therapy&#xD;
&#xD;
          -  History of allergic or adverse response to anti-IL-5 therapy&#xD;
&#xD;
          -  Evidence of, or history of, a parasitic infection (within past 1 year)&#xD;
&#xD;
          -  Participation in a previous clinical trial involving an investigational agent within&#xD;
             30 days prior to study initiation&#xD;
&#xD;
          -  Receipt of anti-IL-5 therapy in the past&#xD;
&#xD;
          -  Blood donation of 450 ml (1 pint) or more within 30 days prior to study initiation&#xD;
&#xD;
          -  Abnormal or unusual diet or substantial changes in eating habits within 30 days prior&#xD;
             to, or during, the study.&#xD;
&#xD;
          -  Patients who do not have eosinophil levels &gt; 750 cells/mcl after the run-in period.&#xD;
             Patients who have only eosinophilic infiltration of tissue are eligible if they do not&#xD;
             develop an eosinophil level &gt; 750 cells/mcl, assuming that they meet all other&#xD;
             eligibility requirements.&#xD;
&#xD;
          -  Positive serum pregnancy test&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Unable to use effective birth control methods for duration of study&#xD;
&#xD;
          -  Unable or unwilling to give voluntary informed consent/assent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc E. Rothenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 15, 2005</study_first_submitted>
  <study_first_submitted_qc>December 15, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2005</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Gastroenteritis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

